Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Invivyd, Inc.
  6. News
  7. Summary
    IVVD   US00534A1025

INVIVYD, INC.

(IVVD)
  Report
Delayed Nasdaq  -  04:00 2022-09-23 pm EDT
2.970 USD   -9.17%
09/13INVIVYD, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
AQ
09/13Invivyd, Inc. has Changed its Ticker to IVVD from ADGI
CI
09/13Adagio Therapeutics, Inc. has Changed its Name to Invivyd, Inc
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Stifel Adjusts Adagio Therapeutics' Price Target to $5 From $9, Reiterates Hold Rating

05/16/2022 | 05:41am EDT


© MT Newswires 2022
All news about INVIVYD, INC.
09/13INVIVYD, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial..
AQ
09/13Invivyd, Inc. has Changed its Ticker to IVVD from ADGI
CI
09/13Adagio Therapeutics, Inc. has Changed its Name to Invivyd, Inc
CI
09/12ADAGIO THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
09/12Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Com..
GL
09/12Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Com..
AQ
09/12Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Com..
CI
09/12Adagio Therapeutics Announces Corporate Name Change to Invivyd
GL
09/12Adagio Therapeutics Announces Corporate Name Change to Invivyd
AQ
09/06Adagio Therapeutics to Participate in Upcoming Investor Conferences
GL
More news
Analyst Recommendations on INVIVYD, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -262 M - -
Net cash 2022 381 M - -
P/E ratio 2022 -1,24x
Yield 2022 -
Capitalization 323 M 323 M -
EV / Sales 2022 -
EV / Sales 2023 14,5x
Nbr of Employees 102
Free-Float 66,6%
Chart INVIVYD, INC.
Duration : Period :
Invivyd, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INVIVYD, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 4
Last Close Price 2,97 $
Average target price 3,83 $
Spread / Average Target 29,1%
EPS Revisions
Managers and Directors
David Hering Chief Executive Officer & Director
Jane Pritchett V. Henderson Chief Financial Officer
Marc W. Elia Chairman
Laura Walker Chief Scientific Officer
Rebecca L. Dabora Chief Technology & Manufacturing Officer
Sector and Competitors
1st jan.Capi. (M$)
INVIVYD, INC.-59.09%323
GILEAD SCIENCES, INC.-13.43%78 787
REGENERON PHARMACEUTICALS, INC.10.42%74 550
VERTEX PHARMACEUTICALS29.08%72 693
BIONTECH SE-50.21%31 192
WUXI APPTEC CO., LTD.-41.46%28 154